196 related articles for article (PubMed ID: 37461332)
1. Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non-cirrhotic patients with chronic hepatitis B.
Lee CH; Lee YB; Moon H; Chung JW; Cho EJ; Lee JH; Yu SJ; Kim YJ; Lee J; Yoon JH
Aliment Pharmacol Ther; 2023 Oct; 58(7):704-714. PubMed ID: 37461332
[TBL] [Abstract][Full Text] [Related]
2. Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis.
Jang H; Lee YB; Moon H; Chung JW; Nam JY; Cho EJ; Lee JH; Yu SJ; Kim YJ; Lee J; Yoon JH
Hepatology; 2022 Aug; 76(2):492-501. PubMed ID: 35100447
[TBL] [Abstract][Full Text] [Related]
3. Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
Lee TY; Hsu YC; Tseng HC; Yu SH; Lin JT; Wu MS; Wu CY
JAMA Intern Med; 2019 May; 179(5):633-640. PubMed ID: 30882847
[TBL] [Abstract][Full Text] [Related]
4. Association of Metabolic Risk Factors With Risks of Cancer and All-Cause Mortality in Patients With Chronic Hepatitis B.
Lee YB; Moon H; Lee JH; Cho EJ; Yu SJ; Kim YJ; Zoulim F; Lee J; Yoon JH
Hepatology; 2021 Jun; 73(6):2266-2277. PubMed ID: 33140415
[TBL] [Abstract][Full Text] [Related]
5. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
6. Clinical Indication of Aspirin Associated With Reduced Risk of Liver Cancer in Chronic Hepatitis B: A Nationwide Cohort Study.
Yun B; Ahn SH; Yoon JH; Kim BK
Am J Gastroenterol; 2022 May; 117(5):758-768. PubMed ID: 35294425
[TBL] [Abstract][Full Text] [Related]
7. Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog.
Hui VW; Yip TC; Wong VW; Tse YK; Chan HL; Lui GC; Wong GL
Clin Transl Gastroenterol; 2021 Mar; 12(3):e00324. PubMed ID: 33750746
[TBL] [Abstract][Full Text] [Related]
8. Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study.
Choi WM; Kim HJ; Jo AJ; Choi SH; Han S; Ko MJ; Lim YS
Liver Int; 2021 Nov; 41(11):2777-2785. PubMed ID: 34242482
[TBL] [Abstract][Full Text] [Related]
9. Statin use and the risk of hepatocellular carcinoma among patients with chronic hepatitis B: an emulated target trial using longitudinal nationwide population cohort data.
Sinn DH; Kang D; Park Y; Kim H; Hong YS; Cho J; Gwak GY
BMC Gastroenterol; 2023 Oct; 23(1):366. PubMed ID: 37880589
[TBL] [Abstract][Full Text] [Related]
10. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
Choi J; Kim HJ; Lee J; Cho S; Ko MJ; Lim YS
JAMA Oncol; 2019 Jan; 5(1):30-36. PubMed ID: 30267080
[TBL] [Abstract][Full Text] [Related]
11. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
Zhang W; Wang X; Wang Y; Zhao X; Duan W; Wang Q; Wu X; Kong Y; Ma H; You H; Ou X; Jia J
Medicine (Baltimore); 2017 Nov; 96(44):e8454. PubMed ID: 29095292
[TBL] [Abstract][Full Text] [Related]
12. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
[TBL] [Abstract][Full Text] [Related]
13. Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients.
Cho YY; Lee JH; Chang Y; Nam JY; Cho H; Lee DH; Cho EJ; Lee DH; Yu SJ; Lee JM; Kim YJ; Yoon JH
J Viral Hepat; 2018 Oct; 25(10):1161-1171. PubMed ID: 29741286
[TBL] [Abstract][Full Text] [Related]
14. Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study.
Nguyen MH; Yang HI; Le A; Henry L; Nguyen N; Lee MH; Zhang J; Wong C; Wong C; Trinh H
J Infect Dis; 2019 Jan; 219(1):10-18. PubMed ID: 29982737
[TBL] [Abstract][Full Text] [Related]
15. Association of Daily Aspirin Therapy With Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis C Virus Infection.
Lee TY; Hsu YC; Tseng HC; Lin JT; Wu MS; Wu CY
Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2784-2792.e7. PubMed ID: 32360983
[TBL] [Abstract][Full Text] [Related]
16. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
Kim GA; Han S; Kim HD; An J; Lim YS
J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
[TBL] [Abstract][Full Text] [Related]
17. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.
Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liao SH; Hong CM; Liu CH; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
Hepatol Int; 2023 Oct; 17(5):1139-1149. PubMed ID: 37247045
[TBL] [Abstract][Full Text] [Related]
18. [Risk analysis for hepatocellular carcinoma in patients with chronic hepatitis B-associated cirrhosis complicated by type 2 diabetes mellitus: a 5-year prospective cohort study].
Tang C; Hu C; Zhou Y; Song Y; Li M; Liao M; Sun J; Zhong C; Zhou L; Lin Z; Zhou Y
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Mar; 41(3):313-318. PubMed ID: 33849820
[TBL] [Abstract][Full Text] [Related]
19. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment.
Tseng TC; Choi J; Nguyen MH; Peng CY; Siakavellas S; Papatheodoridis G; Wang CC; Lim YS; Lai HC; Trinh HN; Wong C; Wong C; Zhang J; Li J; Kao JH
Hepatol Int; 2021 Feb; 15(1):105-113. PubMed ID: 33547557
[TBL] [Abstract][Full Text] [Related]
20. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals.
Lee HW; Kim SU; Park JY; Baatarkhuu O; Kim DY; Ahn SH; Han KH; Kim BK
Clin Transl Gastroenterol; 2019 Jun; 10(6):e00036. PubMed ID: 31107725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
